Stocks News

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Sector Update: Health Care Stocks Edge Higher Late Afternoon, from 20 hours ago by MT Newswires
  20 hours ago by MT Newswires
  Companies Mentioned: GSK, UNH, KOD, EDIT
  03:56 PM EST, 12/09/2024 (MT Newswires) -- Health care stocks edged up late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) rose 0.5%. In co...
- Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated', from 12:25PM ET on Monday Dec 09, 2024 by MT Newswires
  12:25PM ET on Monday Dec 09, 2024 by MT Newswires
  Companies Mentioned: EDIT
  12:25 PM EST, 12/09/2024 (MT Newswires) -- Editas Medicine (EDIT) shares were up almost 7% in recent trading Monday after the company said that its renizgamglogene autogedtemcel, or reni-cel, therapy continued to be well-tolerated in sickle cell dis...
- Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting, from 12:00PM ET on Monday Dec 09, 2024 by Dow Jones
  12:00PM ET on Monday Dec 09, 2024 by Dow Jones
  Companies Mentioned: EDIT
  
  Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Nov 25, 2024
- BofA Securities Downgrades Editas Medicine to Underperform, from 7:51AM ET on Monday Nov 25, 2024 by MT Newswires
  7:51AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: EDIT
  07:51 AM EST, 11/25/2024 (MT Newswires) -- Editas Medicine (EDIT) has an average rating of overweight and mean price target of $8.15, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ba...

Today
- HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target, from 5 hours ago by MT Newswires
  5 hours ago by MT Newswires
  Companies Mentioned: NKTR
Yesterday
- Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus, from 10:32AM ET on Monday Dec 09, 2024 by MT Newswires
  10:32AM ET on Monday Dec 09, 2024 by MT Newswires
  Companies Mentioned: ENTA
- DJ Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials, from 7:12AM ET on Monday Dec 09, 2024 by Dow Jones
  7:12AM ET on Monday Dec 09, 2024 by Dow Jones
  Companies Mentioned: ENTA
- Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV), from 6:30AM ET on Monday Dec 09, 2024 by Dow Jones
  6:30AM ET on Monday Dec 09, 2024 by Dow Jones
  Companies Mentioned: ENTA
Dec 7, 2024
- Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting, from 12:00PM ET on Saturday Dec 07, 2024 by PR Newswire
  12:00PM ET on Saturday Dec 07, 2024 by PR Newswire
  Companies Mentioned: NKTR
- Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting, from 12:00PM ET on Saturday Dec 07, 2024 by Dow Jones
  12:00PM ET on Saturday Dec 07, 2024 by Dow Jones
  Companies Mentioned: NKTR
Dec 6, 2024
- Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV), from 5:00PM ET on Friday Dec 06, 2024 by Dow Jones
  5:00PM ET on Friday Dec 06, 2024 by Dow Jones
  Companies Mentioned: ENTA
Nov 27, 2024
- Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $14 From $16, Maintains Perform Rating, from 8:29AM ET on Wednesday Nov 27, 2024 by MT Newswires
  8:29AM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: ENTA
Nov 26, 2024
- DJ Enanta Pharmaceuticals Is Maintained at Outperform by Baird, from 11:19AM ET on Tuesday Nov 26, 2024 by Dow Jones
  11:19AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: ENTA
- DJ Enanta Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by JMP Securities, from 8:03AM ET on Tuesday Nov 26, 2024 by Dow Jones
  8:03AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: ENTA

Editas Medicine Inc
NASDAQ:EDITUnited States

Search Criteria

Yesterday

Sector Update: Health Care Stocks Edge Higher Late Afternoon, from 20 hours ago by MT Newswires

Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated', from 12:25PM ET on Monday Dec 09, 2024 by MT Newswires

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting, from 12:00PM ET on Monday Dec 09, 2024 by Dow Jones

Nov 25, 2024

BofA Securities Downgrades Editas Medicine to Underperform, from 7:51AM ET on Monday Nov 25, 2024 by MT Newswires

Peers Headlines

Today

HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target, from 5 hours ago by MT Newswires

Yesterday

Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus, from 10:32AM ET on Monday Dec 09, 2024 by MT Newswires

DJ Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials, from 7:12AM ET on Monday Dec 09, 2024 by Dow Jones

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV), from 6:30AM ET on Monday Dec 09, 2024 by Dow Jones

Dec 7, 2024

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting, from 12:00PM ET on Saturday Dec 07, 2024 by PR Newswire

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting, from 12:00PM ET on Saturday Dec 07, 2024 by Dow Jones

Dec 6, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV), from 5:00PM ET on Friday Dec 06, 2024 by Dow Jones

Nov 27, 2024

Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $14 From $16, Maintains Perform Rating, from 8:29AM ET on Wednesday Nov 27, 2024 by MT Newswires

Nov 26, 2024

DJ Enanta Pharmaceuticals Is Maintained at Outperform by Baird, from 11:19AM ET on Tuesday Nov 26, 2024 by Dow Jones

DJ Enanta Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by JMP Securities, from 8:03AM ET on Tuesday Nov 26, 2024 by Dow Jones